Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport®) for the relief of upper back myofascial pain syndrome: Results from a randomized double-blind placebo-controlled multicentre study

Hartmut Göbel, Axel Heinze, Gerhard Reichel, Harald Hefter, Reiner Benecke and on behalf of the Dysport myofascial pain study group

Botulinum type A toxin (BoNT-A) has antinociceptive and muscle-relaxant properties and may help relieve the symptoms of myofascial pain syndrome. This study evaluated the efficacy and tolerability of BoNT-A  (Dysport®) in patients with myofascial pain syndrome of the upper back. Patients with moderate-to-severe myofascial pain syndrome affecting cervical and/or shoulder muscles were randomized to BoNT-A or saline injections which were made into the 10 most tender trigger points. The results showed that BoNT-A resulted in a significantly less pain in all outcomes. The authors conclude that in patients with upper back myofascial pain syndrome, injections of 400 Ipsen units of Dysport® at 10 individualised trigger points significantly improved pain levels 4–6 weeks after treatment.

Pain, Volume 125, Issues 1-2, November 2006, Pages 82-88

View Abstract

Full article with Athens login

Neck Pain

Out of all 291 conditions studied in the Global Burden of Disease 2010 Study, neck pain ranked 4th highest in terms of disability and 21st in terms of overall burden.

Speak your mind

Your email will not be published.